# AN2 Therapeutics, Inc. (ANTX): MoatMap facts

As of 27 Oct 2026. Research data, not investment advice.

As of 27 Oct 2026, MoatMap's StockRank for AN2 Therapeutics, Inc. (ANTX) is 22/100, ranked against 24,000+ stocks in 35 markets (Quality 32, Value 31, Momentum 43, each scored against its sector).

- StockRank: 22/100, a percentile across 24,000+ stocks in 35 markets (100 is best).
- Quality 32, Value 31, Momentum 43: each a 0-100 percentile within Healthcare.
- Position: #20,562 overall, #1,838 in Healthcare.
- Listing: United States, NMS; Healthcare / Biotechnology.
- Last close: 3.63 USD on 26 Oct 2026.
- Insider filings, last 180 days: directors bought USD 12K; directors sold USD 344K.

Source: https://moatmap.ai/stock/ANTX
How the scores work: https://moatmap.ai/methodology
Does StockRank work? The public record: https://moatmap.ai/decile-tracker